TARO

Taro Pharmaceutical Industries Ltd.

37.97 USD

Last updated Dec 10, 01:30 UTC

Yesterday HIGH

$38.32

Yesterday LOW

$37.13

52w HIGH

$42.22

52w LOW

$22.89

EPS

0.38

PE

99.92

Next Earnings

Jan 23, 2024

Overview News Government Trades

Taro Pharmaceutical Industries Ltd. stock is up 11.38% since 30 days ago. The next earnings date is Jan 23, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 58.33% of the previous 11 December’s closed higher than November.

Taro Pharmaceutical Industries Ltd. develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It distributes and sells its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, grocery chains, and other direct purchasers and customers.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

Haifa, Israel

Website

taro.com

Lisa Levin

Tue May 30, 2023

Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.
Benzinga Newsdesk

Mon Mar 27, 2023

Sun Pharma Parent Taro Pharmaceutical Industries Updates On Ransomware Incident

As previously disclosed, on March 1, 2023, Sun Pharmaceutical Industries Ltd. (“Sun”), the parent company of Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro”), disclosed that it is
Benzinga Insights

Wed Mar 15, 2023

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 479 stocks made new 52-week lows.
Benzinga Newsdesk

Wed Jan 25, 2023

HC Wainwright & Co. Maintains Buy on Taro Pharmaceutical Indus, Lowers Price Target to $35

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Taro Pharmaceutical Indus (NYSE:TARO) with a Buy and lowers the price target from $54 to $35.
Michael Horton

Tue Jan 24, 2023

Taro Pharmaceutical Indus Q3 EPS $0.19 May Not Compare To $0.87 Estimate, Sales $139.20M Miss $163.12M Estimate

Taro Pharmaceutical Indus (NYSE:TARO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.87 by 78.16 percent. This is a 72.86 percent decrease over earnings of $0.70 per
Benzinga Insights

Tue Jan 24, 2023

Earnings Scheduled For January 24, 2023

Companies Reporting Before The Bell • GATX (NYSE:GATX) is expected to report quarterly earnings at $1.44 per share on revenue of $327.63 million.
Benzinga Insights

Mon Jan 23, 2023

Taro Pharmaceutical Indus's Earnings Outlook
Benzinga Insights

Thu Oct 27, 2022

Earnings Scheduled For October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Benzinga Insights

Wed Oct 26, 2022

Taro Pharmaceutical Indus's Earnings: A Preview

Taro Pharmaceutical Indus (NYSE:TARO) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.84.
Benzinga Insights

Mon Sep 19, 2022

Stocks That Hit 52-Week Lows On Monday

On Monday, 429 stocks made new 52-week lows.